Detailed CV: Jeffry P. Simko, PhD, MD

Detailed CV: Jeffry P. Simko, PhD, MD
University of California San Francisco
CURRICULUM VITAE
Prepared: 5-21-2015
Name:
Jeffry P. Simko, MD, PhD
Positions:
Professor of Clinical Pathology, Step 2 (effective 7/1/15)
Department of Anatomic Pathology, School of Medicine
Professor of Clinical Pathology, Department of Urology (secondary)
Professor of Clinical Pathology, Dept. of Radiation Oncology (secondary)
Associate, UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC)
Director, Genitourinary Oncology Program Tissue Core (HDFCCC)
Chair, UCSF Genitourinary Tissue Utilization Committee (HDFCCC)
Associate Director, RTOG Biospecimen Resource (An NCI Sponsored National
Cooperative Group Resource)
Director, UCSF Molecular Genetic Pathology Fellowship Program
Address:
UCSF at Mission Bay
1825 4th Street, Room M-2360
San Francisco, CA 94143-4066
Ph: (415) 353-7581
Pg: (415) 443-0534
FAX: (415) 353-1612
Email: jeff.simko@ucsf.edu
http://www.ucsf.edu/pathol/people/simko.htm
http://cc.ucsf.edu/people/simko_jeffry.html
EDUCATION:
1981 - 1985
1985 - 1990
1992 - 1996
1996 - 2000
2000 - 2001
2001 - 2002
University of Delaware, Newark, DE
University of North Carolina, Chapel Hill, NC
University of North Carolina, Chapel Hill, NC
University of California, San Francisco, CA
Harvard Medical School, Boston, MA
University of California, San Francisco, CA
B.S.
Ph.D.
M.D.
Resident
Fellow
Fellow
Chemistry
Analytical Chemistry
Medicine
Pathology
Molecular Pathology
Surgical Pathology
LICENSES, CERTIFICATION:
1998 - present
2000
2003
Medical License (#A064515), Medical Board of California, Sacramento, CA
Board Certification, Anatomic & Clinical Pathology (#00-309), Am. Board of Pathology
Board Certification, Molecular Genetic Pathology (#1921), American Board of Pathology
PRINCIPAL POSITIONS HELD:
1983 - 1985
1988 - 1990
1991 - 1992
2002 - 2003
Student Employee, Pioneering Research Lab, E.I. du Pont Inc., Wilmington, DE
Visiting Engineer, IBM T.J. Watson Research Center, Yorktown Heights, NY
Research Associate, Frontier Research Program, Institute of Physical and Chemical
Research (RIKEN), Wakou-shi, Saitama, Japan
Assistant Clinical Professor, Dept. of Anatomic Pathology, UC San Francisco
Jeff Simko
2003 - 2007
2003 - 2007
2007 - 2013
2007 - 2013
2011 - 2013
2013 - present
2013 - present
2013 - present
Assistant Professor of Pathology, Dept. of Anatomic Pathology, UC San Francisco
Assistant Professor of Pathology, Department of Urology, UC San Francisco
Associate Professor of Pathology, Dept. of Anatomic Pathology, UC San Francisco
Associate Professor of Pathology, Department of Urology, UC San Francisco
Associate Professor of Pathology, Department of Radiation Oncology, UCSF
Professor of Pathology, Deptartment of Anatomic Pathology, UC San Francisco
Professor of Pathology, Department of Urology, UC San Francisco
Professor of Pathology, Department of Radiation Oncology, UCSF
OTHER POSITIONS HELD CONCURRENTLY (Pathology):
2000 - 2001
2001 - 2002
2000 - 2003
2002 - 2003
7/2002
2002 - present
2002 - present
2002 - present
8/2003
2004
2008 - 2010
2008 - present
2008 - present
2008 - present
2010 - present
2010 - 2012
2014 - present
Clinical Fellow, Molecular Pathology, Brigham and Womens’ Hospital, Boston, MA
Clinical Fellow, Surgical Pathology, UCSF Hospitals, San Francisco, CA
Consultant, Anatomic Pathology, Chiron Corporation, Emeryville, CA
Consultant, Anatomic Pathology, Incyte Genomics Corporation, Palo Alto, CA
Mini-Fellowship, Genitourinary Pathology, with Dr. Victor Reuter, Memorial SloanKettering Cancer Center, New York, NY
Director, Genitourinary Tissue Core, UCSF Comprehensive Cancer Center
Chair, Genitourinary Tissue Utilization Committee, UCSF
Staff Pathologist, UCSF Department of Anatomic Pathology
Mini-Fellowship, Genitourinary Pathology, with Dr. Jonathan Epstein, Johns Hopkins
Medical Institutions, Baltimore, MD
Co-Director, Molecular Pathology Laboratory, UCSF Departments of Anatomic
Pathology and Laboratory Medicine
Chair, South bay Pathology Society (SBPS) Nominating Committee
Associate Director, NRG Oncology Biospecimen Bank (NRG = NSABP-RTOG-GOG),
An NCI Sponsored National Clinical Trial Cooperative Group Resource
NCI Group Banking Committee (GBC) Regulatory Subcommittee Member
NCI GBC Access and Marketing Subcommittee Member
ALLIANCE Pathology Group Cadre Member Pathologist (An NCI Sponsored National
Cooperative Group).
Director, Department of Anatomic Pathology Genitourinary Fellowship Program
Interim Director, UCSF Molecular Genetic Pathology Fellowship Program
OTHER EXPERIENCE (Non-pathology)
1986 - 1990
1993
1993 - 1994
9/94 - 12/94
Research Assistant, University of North Carolina Chapel Hill Chemistry Department
Medical Student Researcher, Department of Biochemistry, UNC School of Medicine
Medical Student Researcher, Dept. of Maternal and Fetal Med, UNC School of Med.
Visiting Scientist, Department of Biophysics, Beijing Medical University, P.R. China
HONORS AND AWARDS:
1984
1994
1994
1994
10/97 - 12/97
4/98 - 6/98
American Chemical Society, U. of Delaware Analytical Chemistry Award
Howard Hughes Trust Fund Fellowship, University of North Carolina SOM
UNC School of Medicine Foreign Fellowship Award
Medical Alumni Association Research Fellowship, UNC School of Medicine
Chief Resident, Department of Anatomic Pathology, SF VA Medical Center
Chief Resident, Department of Anatomic Pathology, SF General Hospital
1
Jeff Simko
3/00 - 6/00
2000
Chief Resident, Department of Laboratory Medicine, SF General Hospital
Travel Award, College of American Pathologists Strategic Science Seminar
KEYWORDS/AREAS OF INTEREST:
General Surgical Pathology, Genitourinary Pathology. Urologic Oncology. Molecular Pathology, Molecular
Diagnostics and Biomarkers of Malignancies, including tumor antigens and antibodies. Radiology-Pathology
Correlations in Genitourinary Malignancy. Tissue Banking
PROFESSIONAL ACTIVITIES
SUMMARY OF CLINICAL ACTIVITIES
2002 - present
2002 - present
2002 - present
2002 - 2007
2004
2006 - 2007
2006 - 2014
2010 - present
2015 - present
Surgical Pathology Clinical Service, UCSF Department of Anatomic Pathology
(evaluation and case sign-out of UCSF patient surgical and biopsy specimens, intraoperative consultations and frozen sections, outside consultations sent to me from
community pathologists; ~21 weeks per year)
Surgical Pathology On-Call Service, UCSF Mission Bay Cancer Center, 2 weeks/year
Urologic Oncology Tumor Board, UCSF Mission Bay, 24 meetings/year
Thoracic Oncology Tumor Board, UCSF Mount Zion Cancer Center, ad hoc, ~3 / year
Co-Director, Molecular Pathology Laboratory, UCSF Clinical Laboratory.
Proctor, Molecular Pathology Laboratory Clinical Faculty.
Head & Neck Tumor Board, UCSF Mission Bay, ad hoc, ~ 3 / year
Proctor, New Surgical Pathology Clinical Faculty.
Molecular Pathology Clinical Staff Member, 2 weeks/year
My clinical service responsibilities are four-fold. First, is participation in the general surgical pathology
service for the Medical Center, and involves evaluation of tissue specimens (surgical and biopsy specimens)
taken from patients undergoing procedures at UCSF. This evaluation includes general histology,
immunohistochemistry and special stains, and intra-operative consultations and frozen section diagnosis, with
reports generated and distributed to clinicians for patient care. This also involves on-call service for
pathologic diagnosis during off-hours. My general surgical pathology service, and my on-call service involve
13 weeks per year and 2 weeks per year respectively. My second responsibility is as the specialist in
genitourinary pathology, and involves participation in urologic oncology tumor board and quality control of
urologic oncology surgical and biopsy specimen handling and sign-out. I’m also a consultant on challenging
pathology cases related to genitourinary oncology , which takes ~6 weeks/year in aggregate. This involves
review of cases from within and outside UCSF, where I’ve been solicited to render an opinion on a case due to
my expertise and experience within this area of pathology. I was also the proctor for faculty responsible for
the clinical molecular pathology laboratory (the Medical Director of this Lab, as well as others), and I’m
currently serving as the proctor for new faculty and clinical instructors (usually from one to four individuals
per year; two individuals in 2014, at least one in 2015) involved in Surgical Pathology case sign-out at UCSF
Mission Bay. This involves review of all of their genitourinary pathology cases for three months each year.
Lastly, as Interim Director of the Molecular Genetic Pathology Fellowship Program, so now I am involved in
weekly signout of molecular tests results for mutation status in solid tumors, roughly 4 to 6 hours every month
at UCSF Mount Zion.
PROFESSIONAL ORGANIZATIONS
Memberships
1991 - 1992
1992 - 1996
2001 - now
Member, Japan Applied Physics Society (JAPS)
Member, American Medical Student Association (AMSA)
Member, US and Canadian Academy of Pathology (USCAP)
2
Jeff Simko
2001 - now
2001 - 2010
2004 - now
2005 - now
2006 - now
2009 - 2010
2014 - now
Pending
Fellow, College of American Pathologists (CAP)
Fellow, American Society of Clinical Pathologists (ASCP)
Associate Member, South Bay Pathology Society (SBPS)
Regular member, California Society of Pathologists (CSP)
Associate Member, American Urologic Association (AUA)
Regular Member, American Association of Cancer Research (AACR)
Member, American Society of Clinical Oncology (ASCO)
International Society of Urologic Pathologists (ISUP)
SERVICE TO PROFESSIONAL PUBLICATIONS:
1992 - 1996
2002 - now
2004
2005
2005
2006
2007 - 2008
2007 - 2011
2010 - now
2012 - now
2013 - now
2014 - now
2015 - now
2015 - now
Associate Editor, FAX: The Medical Student Research Journal (UNC-SOM)
Ad hoc referee, Journal of Urology (more than 30 manuscripts in 13 years)
Ad hoc referee, J. National Comprehensive Cancer Network (1 manuscript in 1 year)
Ad hoc referee, American Journal of Pathology (1 manuscript in 1 year)
Ad hoc referee, Human Pathology (1 manuscript in 1 year)
Ad hoc Referee, Archives of Pathology and Laboratory Medicine (1 script in 1 year)
Ad hoc Referee, Journal of Molecular Diagnostics (3 manuscripts in 2 years).
Ad hoc Referee, European Journal of Urologic Pathology.
Ad hoc Referee, Urology Journal (6 manuscripts in 3 years).
Ad hoc Referee, British Journal of Urology International (1 manuscript in 1 year).
Ad hoc Referee, European Journal of Urology (3-4 manuscripts per year).
Ad hoc Referee, Clinical Cancer Research (CCR: 2-3 manuscripts per year)
Ad hoc Referee, Histopathology ( 1 manuscript in one year).
Ad hoc Referee, Human Pathology Case Reviews (1 manuscript in one year).
INVITED PRESENTATIONS
International
2005
2006
2014
National
2008
2009
2009
2010
2012
2012
2013
2013
3rd Annual Congress of International Drug Discovery Science and Technology (IDDST),
Shanghai, PR China
4th Annual Congress of IDDST, Dalian, PR China
ISUP International Gleason Grading Standardization Convention, Chicago, IL
Pathobiology of Cancer: The Ed Smuckler Memorial Course AACR, Snowmass, CO
Pathobiology of Cancer: The Ed Smuckler Memorial Course AACR, Snowmass, CO
RTOG Semiannual Meeting, Philadelphia, PA (RTOG Tissue Banking Efforts)
American College of Osteopathic Pathology, National Meeting, San Francisco, CA
RTOG Semiannual Meeting, Atlanta GA (Tissue Banks in the Cooperative Groups)
RTOG Semiannual Symposium Organizer, Philadelphia (Next Gen Sequencing in Cooperative
Group Settings)
RTOG Semiannual Meeting, San Diego, CA
RTOG Semiannual Meeting, Philadelphia, PA
Regional and other Invited Presentations
2004
Current Issues in Anatomic Pathology, San Francisco, CA
2004
UCSF Department of Radiation Oncology Grand Rounds, San Francisco, CA
2005
Current Issues in Anatomic Pathology, San Francisco, CA
2005
City of Hope National Medical Center, Duarte, CA
2006
Current Issues in Anatomic Pathology, San Francisco, CA
3
Jeff Simko
2006
2008
2010
2011
2012
2013
2013
2014
2014
2015
Beijing Medical University, Beijing, PR China
Current Issues in Anatomic Pathology, San Francisco, CA
Current Issues in Anatomic Pathology, San Francisco, CA
Guest Professor, Department of Pathology, University of Hawaii Medical School
Current Issues in Anatomic Pathology, San Francisco, CA
Guest Professor, Grand Rounds, Department of Pathology, Harbor-UCLA Med Ctr.
Current Issues in Anatomic Pathology, San Francisco, CA
Current Issues in Anatomic Pathology, San Francisco, CA
Colorado Society of Clinical Pathologists Stars in the Mountains CME, Vail, CO
Current Issues in Anatomic Pathology, San Francisco, CA
CME COURSES ATTENDED
2002
2003
2003
2003
2003
2004
2004
2004
2004
2004
2005
2005
2006
2006
2006
2006
2006
2006
2007
2007
2007
2007
2007
2007
2007
2008
2008
2008
2008
2008
2008
2009
2009
2009
2009
2009
2010
2010
2010
Diagnostic Pathology of Soft Tissue Tumors, Harvard Medical School, Boston, MA
Weekends of Pathology, American Society of Clinical Pathology, San Francisco, CA
American Urological Association Annual Meeting, Chicago, IL
Current Issues in Anatomic Pathology, UCSF-Stanford, San Francisco, CA
California Society of Pathologist’s Annual Meeting, San Francisco, CA
Current Issues in Anatomic Pathology, UCSF-Stanford, San Francisco, CA
US and Canadian Academy of Pathology (USCAP) Annual Meeting, Vancouver, BC
Advances in Urology, UCSF, San Francisco, CA
South Bay Pathology Society Annual Spring Meeting, Monterey, CA
California Society of Pathologist’s Annual Meeting, San Francisco, CA
South Bay Pathology Society Annual Spring Meeting, Monterey, CA
Current Issues in Anatomic Pathology, UCSF-Stanford, San Francisco, CA
ASCO Prostate Cancer Symposium, San Francisco, CA
Controversies in Prostate Cancer Detection, UT MD Anderson, Kohala, HI
South Bay Pathology Society Annual Spring Meeting, Monterey, CA
Current Issues in Anatomic Pathology, UCSF-Stanford, San Francisco, CA
American Society of Clinical Pathology Annual Meeting, Las Vegas, NV
California Society of Pathology Annual Meeting, San Francisco, CA
Current Controversies in Urologic Oncology, UCSF Dept of Urology, SF, CA
Weekends of Pathology, American Society of Clinical Pathology, Las Vegas, NV
Early Stage Prostate Cancer Management, UCSF Dept of Urology, San Francisco, CA
US and Canadian Academy of Pathology (USCAP) Annual Meeting, San Diego, CA
South Bay Pathology Society Annual Spring Meeting, Monterey, CA
Current Issues in Anatomic Pathology, UCSF-Stanford, San Francisco, CA
Association of Molecular Pathology Annual Meeting, Los Angeles, CA
ASCO Genitourinary Cancer Symposium, San Francisco, CA
Current Issues in Anatomic Pathology, UCSF-Stanford, San Francisco, CA
South Bay Pathology Society Annual Spring Meeting, San Francisco, CA
RTOG Semiannual meeting, San Diego, CA
RTOG Semiannual meeting, Philadelphia, PA
California Society of Pathology Annual Meeting, Los Angeles, CA
RTOG Semiannual Meeting, New Orleans, LA
UCSF Department of Urology Annual CME Course, San Francisco, CA
US and Canadian Academy of Pathology (USCAP) Annual Meeting, Boston, MA
South Bay Pathology Society Annual Spring Meeting, Monterey, CA
RTOG Semiannual Meeting, Chicago, IL
RTOG Semiannual Meeting, Tampa, FL
ASCO GU Oncology Symposium, San Francisco, CA
USCAP Annual Meeting, Washington DC
4
Jeff Simko
2010
2010
2010
2010
2011
2011
2011
2011
2012
2012
2012
2012
2012
2012
2012
2013
2013
2013
2013
2013
2013
2013
2014
2014
2014
2014
2014
2014
2014
2014
2014
2014
2015
2015
2015
2015
RTOG Semiannual Meeting, Philadelphia, PA
Current Issues in Anatomic Pathology, San Francisco, CA
California Society of Pathology Annual Meeting, San Francisco, CA
CTTR Annual Symposium, San Francisco, CA
RTOG Semiannual Meeting, San Diego, CA
Current Issues in Anatomic Pathology, San Francisco, CA
RTOG Semiannual Meeting, Philadelphia, PA
California Society of Pathology Annual Meeting (San Francisco, CA)
RTOG Semiannual Meeting, Atlanta, GA
ASCO Genitourinary Symposium (San Francisco, CA)
USCAP Annual Meeting (Vancouver, BC, CN)
Current Issues in Anatomic Pathology, San Francisco, CA
RTOG Semiannual Meeting, Philadelphia, PA
Association of Molecular Pathology Annual Meeting, Long Beach, CA
California Society of Pathology Annual Meeting, San Francisco, CA
RTOG Semiannual Meeting, San Diego, CA
AUA Annual Meeting, San Diego, CA
Southbay Pathology Society Annual Meeting, Monterey, CA
Current Issues in Anatomic Pathology, San Francisco, CA
RTOG Semiannual Meeting, Philadelphia, PA
California Society of Pathology Annual Meeting (San Francisco, CA)
California Tumor Tissue Registry Semi-Annual Seminar (San Francisco, CA)
NRG (RTOG) SemiAnnual Meeting, San Diego, CA
ASCO Genitourinary Symposium (San Francisco, CA)
USCAP Annual Meeting (SanDiego, CA)
Current Issues in Anatomic Pathology, San Francisco, CA
ASCO Annual Meeting, Chicago, IL
NRG (RTOG) SemiAnnual Meeting, Chicago, IL
Colorado Society of Clinical Pathologists Stars in the Mountains, Vail, CO
College of American Pathologists (CAP) Annual Meeting, Chicago, IL
Association of Molecular Pathology (AMP) Annual Meeting, Washington, DC
California Society of Pathology Annual Meeting (San Francisco, CA)
NRG (RTOG) SemiAnnual Meeting, San Diego, CA
USCAP Annual Meeting (Boston, MA)
Current Issues in Anatomic Pathology, San Francisco, CA
NRG (RTOG) SemiAnnual Meeting, Denver, CO
UNIVERSITY AND PUBLIC SERVICE
UNIVERSITY SERVICE
SCHOOL OF MEDICINE
HOSPITAL / MEDICAL CENTER SERVICE
2002 - present
2002 - present
2002 - present
2002 - 2006
2004
2006 - 2008
2006 - 2007
2007 - present
2010 - present
Surgical Pathology Clinical Service, UCSF Department of Pathology, 21 weeks/year
Surgical Pathology On-Call Service, UCSF Mission Bay CCC, 2 weeks/year
Urologic Oncology Tumor Board, UCSF Mount Zion Cancer Center, 25 meetings/year
Thoracic Oncology Tumor Board, UCSF Mount Zion Cancer Center, ad hoc, ~2 / year
Co-Director, Molecular Pathology Laboratory, UCSF Clinical Laboratory.
Gynecologic Tumor Board, UCSF Mount Zion Cancer Center, ad hoc, ~ 2 / year.
Proctor, Molecular Pathology Clinical Faculty.
Gastrointestinal Tract Tumor Board, UCSF Mount Zion Cancer Center, ~ 3 / year.
Proctor, New Surgical Pathology Clinical Faculty (1 or 2 new faculty per year).
5
Jeff Simko
UCSF COMPREHENSIVE CANCER CENTER SERVICE
2002 - now
2002 - now
2002 - now
2002 - 2008
2002 - now
2007
2014 - now
2014 - now
Member, Genitourinary Oncology Program
Chair, UCSF Genitourinary Tissue Utilization Committee
Director, Genitourinary Oncology Program Tissue Core
Member, UCSF Prostate SPORE Project and Core Leaders Group
Member, Tissue Shared Resources Oversight Committee
Member, Academic Recruitment Search Committee
Member, UCSF Molecular Tumor Board Planning Committee
Member, University Tissue Banking Organizational Committee
DEPARTMENT OF ANATOMIC PATHOLOGY SERVICE:
2002 - 2004
2004
2006 - 2007
2010 - 2012
2010 - present
2013
2014 - present
2014 - present
Consultant, Molecular Pathology Laboratory Development
Member, Department of Anatomic Pathology Faculty Search Committee
Proctor, Molecular Pathology Clinical Faculty
Director, Urologic Pathology Fellowship
Proctor, New Surgical Pathology Clinical Faculty.
Member, Department of Anatomic Pathology Faculty Search Committee
Interim Director, UCSF Molecular Genetic Pathology Fellowship Program
Faculty Mentor
DEPARTMENT OF UROLOGY SERVICE:
2008 - present
2010
2013
2014 - present
Director, Bimonthly Urology-Pathology Case Correlation Conference
Member, Faculty Search Committee
Member, Faculty Search Committee
Member, UCSF Prostate SPORE Planning Committee
GOVERNMENT and OTHER PROFESSIONAL SERVICE:
2003 - 2008
2004 - 2005
2005 - present
2007 - 2008
Representative, Prostate SPORE, InterSPORE Biomarkers Working Group (IPBS)
Invited Pathologist, Prostate Atrophy Consensus Working Group
Laboratory Inspector, College of American Pathologists (CAP) (~5-7 per year).
Ad Hoc Reviewer, NIH Grants Review Panel “Cooperative Human Tissue Network”
2008 - present
2008 - present
2008 - 2010
2009 - 2010
2010 - 2011
2010 - present
2010 - present
2012 - present
2013
NCI Group Banking Committee (GBC) Regulatory Subcommittee Member
NCI GBC Access and Marketing Subcommittee Member
Chair, South bay Pathology Society (SBPS) Nominating Committee
Ad Hoc Reviewer, NIH Contracts Review Panel “CTCs Technology”
Grant Reviewer, US Veteran’s Administration Oncology (A) Grant Review Panel
Pathology Cadre Member & Case Reviewer, ALLIANCE (NCI Cooperative Group)
Grant Reviewer, Prostate Cancer Foundation (PCF), Grant Review Panel
Grant Reviewer, Pennsylvania State Department of Health Cure Grant Program
Grant Reviewer, Movember Foundation for Men’s Health, Grant Review Panel
SUMMARY OF UNIVERSITY AND PUBLIC SERVICE ACTIVITIES
My service involvement stems from my experience and abilities in genitourinary pathology, Molecular
Pathology, and tissue banking. I have become heavily involved in the functioning and support of the tissue
6
Jeff Simko
resources in the UCSF Comprehensive Cancer Center and the NRG Oncology Clinical Trials Group (formerly
known as RTOG; Radiation Therapy Oncology Group), one of the five National Clinical Trials Cooperative
Groups for Oncology. This involvement includes oversight of tissue collection, storage and processing, and
quality control measures in order to ensure that the resource is of highest quality without any compromise to
the diagnostic utility of these specimens for clinical decision-making. This also involves acting as advisor to,
and collaborator with researchers wanting to use tissue resources in their projects. These interactions help
optimize effective use of the resource by investigators, and also involve aid in study design and grant proposal
preparation. Besides the obvious offshoot into research collaborations and projects, this experience has also
led to my involvement in a number of committees that directly oversee the management and utilization
activities for research tissues, in order to ensure effective collection and use of these limited resources, which
in turn has led to recognition beyond UCSF and involved in working groups that are trying to standardize
tissue collection and storage protocols across a number of institutions in order to minimize pre-analytical
variables that could lead to confounding results in cross-institutional studies. The ultimate goal of all of this
work is to develop new national standards for tissue collection and processing that will optimize clinical utility
of new biomarkers currently under development. This most recently has lead to, as a member of a group of
pathologists here at UCSF, being awarded the contract to run the NRG Biospecimen Bank, one of only five
NCI funded national cooperative group biospecimen banks.
My experience in Genitourinary Pathology has reached international recognition, as I am invited to participate
in various working groups and conventions that are attempting to standardize Genitourinary Pathology
diagnostic criteria (most notably for prostate cancer), I routinely get asked to review manuscripts submitted to
international journals, I get invited to present at various national and regional CME courses and academic
institutions’ grand rounds, and also invited to review grant submissions for various government (US Veterans’
Administration, State of PennsylvaniaTobacco Funds, State of Florida Tobacco Funds) and charitable
organizations (Prostate Cancer Foundation and Movember Foundation for Men’s Health).
I also volunteer as a Certified Laboratory Inspector for the College of American Pathology (CAP) Laboratory
Accreditation program, which involves travel to other pathology laboratories in the USA and around the world
(e.g. Japan, Singapore, China, etc.) to evaluate their quality control, assurance and safety procedures. CAP is
now planning to expand into certification processes for Tissue Banks, which will involve similar standards and
oversight.
Additional service relates to my experience in molecular pathology, where I was involved in development and
planning of a clinical molecular pathology laboratory, and I also served as the Clinical Proctor for a new
Director of the Molecular Pathology Laboratory, as well as now proctoring new faculty and clinical instructors
in Surgical Pathology Case Sign-out, and acting as the Molecular Genetic pathology Fellowship Program
Director.
TEACHING and MENTORING
FORMAL SCHEDULED CLASSES FOR UCSF STUDENTS:
Qtr
F
Academic Yr
2002 - 2003
Course No. & Title
IDS 102: Organs
F
2002 - 2003
IDS 106: Nutrition and metabolism
F
2003 - 2004
IDS 102: Organs
F
2003 - 2004
IDS 106: Nutrition and metabolism
F-S
2002 - 2003
Course # 150.03: Surgical
pathology and autopsy pathology
Teaching Contribution
Student assistance with Lab teaching
goals
Student assistance with Lab teaching
goals
Lab section leader and discussion
leader
Lab section leader and discussion
leader
Two hour informal lecture to medical
students interested in pathology
7
Units
4 hrs.
Class Size
~20
5 hrs.
~20
6 hrs.
~30
5 hrs.
~20
8 hrs.
2-3
Jeff Simko
F-S
2003 – 2004
F
2004 - 2005
Course # 150.03: Surgical
pathology and autopsy pathology
IDS 106: Nutrition and metabolism
S
2004 - 2005
IDS 102: Organs
S
2004 - 2005
IDS 103: Cancer
F-S
2004 - 2005
F-S
2005-2006
Course # 150.03: Surgical &
Autopsy Pathology
IDS 106: Nutrition & Metabolism
F-S
2005-2006
F
2006
Course # 150.03: Surgical &
Autopsy Pathology
IDS 106: Cancer, bench to bedside
S
2007
IDS 103: Metabolism & Nutrition
F
2007
IDS 106: Cancer, bench to bedside
S
2008
IDS 103: Metabolism & Nutrition
F-S
2007-2008
S
2009
Course # 150.03: Surgical &
Autopsy Pathology
IDS 103: Metabolism & Nutrition
F
2009
IDS 105: Hypersensitivity &Reject
S
2010
IDS 103: Metabolism & Nutrition
F
2010
I3: Hypersensitivity &Rejection
F
2010
M3: Prostate Cancer
S
2011
102B: Organs (renal &urinalysis)
S
2012
102B: Organs (renal & urinalysis)
S
2013
102B: Organs (renal & urinalysis)
S
2014
102B: Organs (renal & urinalysis)
S
2015
102B: Organs (renal & urinalysis)
Two hour informal lecture to medical
students interested in pathology
Lab section leader and discussion
leader
Lab section leader and discussion
leader
Lab section leader and discussion
leader
Two hour informal lecture to medical
students interested in pathology
Lab section leader and discussion
leader
Two hour informal lecture to medical
students interested in pathology
Lab section leader and discussion
leader
Lab section leader and discussion
leader
Lab section leader and discussion
leader
Lab section leader and discussion
leader
Two hour informal lecture to medical
students interested in pathology
Lab section leader and discussion
leader
Lab section leader and discussion
leader
Lab section leader and discussion
leader
Lab section leader and discussion
leader
Lab section leader and discussion
leader
Lab section leader and discussion
leader
Lab section leader and discussion
leader
Lab section leader and discussion
leader
Lab section leader and discussion
leader
Lab section leader and discussion
leader
8 hrs.
2-3
6 hrs.
~30
4 hrs.
~30
4 hrs.
~20
8 hrs.
1–3
8 hrs.
~20
8 hrs.
1–3
4 hrs.
~20
4 hrs.
~20
4 hrs.
~20
6 hrs.
~20
6 hrs.
1-3 / session
4 hrs.
~20
2 hrs.
~20
8 hrs.
~20
2 hrs.
~ 20
2 hrs.
~ 20
2 hrs.
~ 20
2 hrs.
~ 20
2 hrs.
~ 20
2 hrs.
~ 20
2 hrs.
~ 20
POSTDOCTORAL FELLOWS AND RESIDENTS DIRECTLY SUPERVISED OR MENTORED:
Dates
2003 2006
2004
2005 2006
2007
2007 2010
Name
Jeff Hom, MD
Status
Med Student
Faculty Role
Research Supervision
Current Position
Instructor, Stanford Hospitals
Dean Joelson, MD
Antonio Westphalen, MD
Resident
Clinical Fellow
Clinical Res Supervis
Research Supervision
Javier Rangel, MD
Medical
Student
Resident
Research Supervision
Staff Pathologist, Atlanta, GA
Assoc. Prof in Residence, UCSF
Dept. of Radiology
Staff MD, Redwood Dermatology
John Jalas, MD
Research Supervision
8
Staff Pathologist, Sant Monica
CA
Jeff Simko
2008 2010
2010 2011
2010 2012
2014
2014 2015
2015 2016
2016 2017
Anobel Odisho
Medical student
Research Supervision
Resident, UCSF Urol.
Mike Bonham, MD, PhD
Fellow
Samuel Washington
Medical
Student
Clinical Fellow
Clinical Fellow
Clinical and Research
Supervision
Research Supervision
Staff Pathologist, Genomic
Health, Inc, Redwood City, CA
Resident, UCSF Urol.
Program Director
Program Director
Faculty UCSF Anat. Pathology
Current Clinical MGP Fellow
Clinical Fellow
Program Director
Future Clinical MGP Fellow
Clinical Fellow
Program Director
Molecular Genetic Pathol Fellow
Nancy Joseph, MD, PhD
Zoltan Nagymanyoki, MD,
PhD
Cheryl Mather, MD
Pending interviews
FACULTY OFFICIALLY MENTORED
Dates
7-1-2014 - present
Name
Nancy Joseph, PhD, MD
Current status
Assistant Professor Clinical Pathology
INFORMAL TEACHING:
RESIDENT TEACHING
2002 - present Surgical Pathology Case sign-out (the daily review of histology from patient’s surgical
specimens and biopsies with a pathology resident; the core of resident and fellow education,
760 hours this year, 630 hours last year)
2010 - 2012
Director, Urologic Pathology Fellowship Program: Direct, and Mentor a Pathology Fellow in
developing skills specific to the diagnosis of urologic malignancies and other pathologic
processes (240 hours a year).
2014 - present Interim Director, UCSF Molecular Genetic Pathology Fellowship Program
TEACHING AIDS:
Kidney Tumor Slide Study Set
Bladder Tumor Slide Study Set
Prostate Tumor Slide Study Set
Irradiated Prostate Tumor Slide Study Set
OTHER:
TEACHING PRESENTATIONS AND LECTURES
2000 - 2001
2002 - 2003
2002 - 2004
2002 - 2005
2002 - present
2002 - present
Oncology Fellows’ Core Pathology Education Lecture Series, Dana-Farber Cancer Institute,
Boston: Three lectures on molecular diagnostics for leukemias and lymphomas
Basic Pathology Lecture Series, UCSF Department of Urology (Three lectures on basic pathology
of the genitourinary system to Urology Residents: 4 hours per year)
Molecular Diagnostic Pathology and Cytogenetics, UCSF Department of Lab Medicine (Lecture
in the core lecture series to residents, 2 hours per year)
UCSF Prostate SPORE Working Scientists Meeting (Lecture to Graduate Students, Post-doc’s
and junior faculty working on Prostate Cancer Research, 2 hours per year)
Genitourinary Clinical Conference Lectures (Lectures to members of the Genitourinary Oncology
Service on Pathology Issues, 2 hours/per year)
Urologic Oncology Tumor Board, UCSF Mission Bay, 26 meetings/year
9
Jeff Simko
2004 - present
Genitourinary Surgical Pathology, Grossing Techniques and Molecular Pathology, UCSF
Department of Anatomic Pathology (9 Lectures in core lecture series to residents, 9 hours per
year)
2004 - present Resident Unknown Slide Conference, UCSF Department of Pathology, 2 hrs./yr.
2004
Current Issues in Anatomic Pathology (UCSF CME Course), San Francisco, CA
2004
UCSF Department of Radiation Oncology Grand Rounds, San Francisco, CA
2005
Current Issues in Anatomic Pathology (UCSF CME Course), San Francisco, CA
2006
Current Issues in Anatomic Pathology (UCSF CME Course), San Francisco, CA
2008
Current Issues in Anatomic Pathology (UCSF CME Course), San Francisco, CA
2008
Pathobiology of Cancer: The Ed Smuckler Memorial Course AACR, Snowmass CO
2009
Pathobiology of Cancer: The Ed Smuckler Memorial Course AACR, Snowmass CO
2010
Current Issues in Anatomic Pathology, San Francisco, CA
2010
American College of Osteopathic Pathology, National Meeting, San Francisco, CA
2011
Guest Professor, Department of Pathology, University of Hawaii Medical School
2012
Current Issues in Anatomic Pathology, San Francisco, CA
2012
RTOG Semiannual Symposium Organizer, Philadelphia (Next Gen Sequencing in Cooperative
group settings)
2013
Current Issues in Anatomic Pathology, San Francisco, CA
2013 - present Guest Professor, Grand Rounds, Department of Pathology, Harbor-UCLA Medical Ctr (one
hour lecture and one hour resident meeting per year).
2013 - present UCSF Department of Radiation Oncology Grand Rounds, San Francisco, CA (a one hour
lecture each year)
2014
Current Issues in Anatomic Pathology, San Francisco, CA
2014
Guest Lecturer: Colorado Society of Clinical Pathologists Stars in the Mountains CME
2014
Guest Professor, Grand Rounds, Department of Pathology, Harbor-UCLA Medical Ctr.
2014
International Society of Urologic Pathologists (ISUP) Prostate Grading Standardization
Convention, Chicago, IL
2015
Current Issues in Anatomic Pathology, San Francisco, CA
SUMMARY OF TEACHING HOURS:
2003 - 2004:
664 total hours of teaching (not including preparation).
Formal class, course and lecture teaching hours: 52 hours
Informal teaching hours: 528 hours
Mentoring hours: 84 hours
2004 -2005:
598 total hours of teaching (not including preparation).
Formal class, course and lecture teaching hours: 40 hours
Informal teaching hours: 548 hours
Mentoring hours: 10 hours
2005 - 2006
594 total hours of teaching (not including preparation).
Formal class, course and lecture teaching hours: 30 hours
Informal teaching hours: 544 hours.
Mentoring hours: 20 hours.
2006 - 2007
604 hours (not including preparation).
Formal class, course and lecture teaching hours: 30 hours
Informal teaching hours: 564 hours
Mentoring hours: 10 hours
10
Jeff Simko
2007 - 2008
649 hours (not including preparation).
Formal class, course and lecture teaching hours: 29 hours
Informal teaching hours: 618 hours
Mentoring hours: 2 hours
2008 - 2009
660 hours (not including preparation).
Formal class, course and lecture teaching hours: 29 hours
Informal teaching hours: 629 hours
Mentoring hours: 2 hours
2009 - 2010
620 hours (not including preparation).
Formal class, course and lecture teaching hours: 21 hours
Informal teaching hours: 597 hours
Mentoring hours: 2 hours
2010 - 2011
792 hours (not including preparation).
Formal class, course and lecture teaching hours: 16 hours
Informal teaching hours: 770 hours
Mentoring hours: 6 hours
2011 - 2012
608 hours (not including preparation).
Formal class, course and lecture teaching hours: 14 hours
Informal teaching hours: 594 hours
Mentoring hours: 2 hours
2012 - 2013
630 hours.
Formal class, course and lecture teaching hours: 20 hours
Informal teaching hours: 600 hours
Mentoring hours: 10 hours
2013 - 2014
692 hours.
Formal class, course and lecture teaching hours: 22 hours
Informal teaching hours: 630 hours
Mentoring hours: 40 hours
2014 - 2015
883 hours.
Formal class, course and lecture teaching hours: 18 hours
Informal teaching hours: 795 hours
Mentoring hours (Proctoring): 50 hours
Mentoring hours (Academic mentor): 20 hours
2015 - 2016
847 hours (planned, not including preparation).
Formal class, course and lecture teaching hours: 18 hours
Informal teaching hours: 795 hours
Mentoring hours (Proctoring): 30 hours
Mentoring hours (Academic mentoring): 4 hours
TEACHING NARRATIVE
My teaching responsibilities at UCSF predominantly involve the one-on-one teaching of the practice of
surgical pathology to residents, fellows and medical students in the Department of Anatomic Pathology
through daily sign out of patients’ surgical specimens (scheduled to be 520 hours per year in ’15-‘16). This is
the backbone of pathology resident education, and involves teaching gross diagnosis, dissection and tissue
11
Jeff Simko
handling and preparation, histology and special stain evaluation and interpretation, writing of microscopic
descriptions and pathology reports, communication of findings to clinicians for optimizing patient care, and
frozen section preparation, interpretation and reporting. This effort has expanded due to increased requests for
expert consultation of difficult cases referred to me by internal faculty and external community pathologists
and includes unscheduled involvement of residents and fellows (4 weeks per year with trainees involved).
This effort was extended to the Urologic Pathology Fellowship that I was in charge of in 2010-2011. This
involved one-on-one instruction of a pathology fellow in the field of urologic pathology and such patient
management (~240 hours), with the graduate (Dr. Mike Bonham) going on to become the Director of a large
regional pathology reference lab. I give lectures to residents and fellows (Department of Anatomic Pathology,
Urology and Radiation Oncology (15 hours per year)) on topics in genitourinary surgical pathology (prostate
pathology, bladder pathology, kidney pathology) and molecular diagnostic pathology (cytogenetics and related
technologies (FISH), and PCR-based testing). I present pathology to faculty, residents and fellows at the
twice-monthly Urologic Oncology Tumor Board, which involves describing pertinent findings and pathology
issues for the cases being presented, and also discuss developments in surgical pathology practice that may
have an impact on the clinicians’ practices (25 hours per year), as well as directing the bimonthly UrologyPathology Case Correlation conference where I present interesting findings and pathology issues to the
Urology fellows and residents that is also useful in their Urology Board Exam preparations (10 hours per
year). I participate in the pathology sections of the medical student core curriculum and electives, which
involves helping the students to understand and carry out their laboratory assignments, and giving a small
lecture to them at the end of each session in order to summarize the important points (2 hours per year). I’ve
been an invited speaker every year for the annual UCSF Department of Pathology Annual CME course,
“Current Issues in Anatomic Pathology,” where I’ve given lectures to community pathologists on issues
regarding genitourinary tumors. This has expanded to where I am invited to present similar teaching lectures
at other University Residency Training Programs as guest faculty, as well as other CME courses on occasion
(roughly 4 hours per year). I’ve been given responsibility of proctoring new faculty and clinical instructors in
the appropriate handling and reporting of genitourinary Pathology cases at UCSF. This involves review of all
of their cases over the first three months of their service time (~ 30 hours per year per faculty member
proctored). Lastly, I am now the acting director of the Moleculear Genetic Pathology Fellowship Program at
UCSF, and as such, I’m responsible for mentoring and guiding the fellow through the program and will meet
with him, as well as perform sign-out of molecular pathology cases with him, on a weekly basis (roughly 80
hours per year). Future teaching activities will continue along these lines.
RESEARCH AND CREATIVE ACTIVITIES
RESEARCH AWARDS AND GRANTS (last 5 years)
ACTIVE
07/01/15 - 6/30/20
10%
U24 CA114734 (Jordan)
NIH/NCI: NRG Oncology Biospecimen Bank
RTOG Tissue Bank/Biospecimen Repository: Manage this national cooperative group tissue bank and interact
with the RTOG investigators on collaborative translational research projects.
Role: Co-Investigator (Associate Director)
1R01CA163012-01 (Fong)
09/01/12 - 08/31/17
5%
NIH/NCI
$250,000 ADC
Prostatitis and Prostate Cancer Development
The goal of this project is to determine the frequency of antibody and T cell immune responses to novel
prostate autoantigens in patients with prostate cancer.
Role: Co-Investigator
R01 (Noworolski)
04/01/10 - 03/31/15
NIH/NCI
$254,940
DCE MRI to Improve Prostate Cancer Identification and Characterization
12
1.2%
Jeff Simko
The goals of this grant are to improve the identification and characterization of aggressiveness of prostate
cancer by utilizing novel pharmacokinetic and statistical models.
Role: Co-investigator
R01 CA137207 (Kurhanewicz)
01/01/11 - 06/30/15
2.5%
NIH
Translation and Evaluation of a Multi-parametric Prostate Cancer 3T MRI Exam
The overall goal of this academic-industrial partnership is to improve the clinical imaging assessment
of prostate cancer patients by creating a clinically optimized and validated commercial 3T multi-parametric
(T2 MRI, 1H and hyperpolarized 13C MRSI, DTI and DCE) imaging exam for widespread distribution.
Role: Co-Investigator
W81XWH-13-2-0074 (Carroll)
09/30/13 - 09/29/16
27.27%
DOD TIA Award
Title: Development, Validation, and Dissemination of an Integrated Risk Prediction Model and Decision Aid
to Discern Aggressive Versus Indolent Prostrate Cancer.
The goal of this grant is to improve prediction of under-sampled aggressive disease at biopsy among men with
clinical features consistent with low-risk disease. Given the goal of near-term translatable impact on patient
care, we are focusing on the clinically relevant outcome of upgrading or upstaging between biopsy and
subsequent clinic pathological assessment.
Role: Co-Investigator
PENDING
R01 (Liu)
5%
NIH
Mapping a Clinically Significant Internalizing Tumor Epitope Space
The goal is to develop antibody library-based methods which promote efficient identification of clinically
relevant tumor specific cell surface antigens, methods which are applicable to the identification of cell typespecific lineage markers in general.
Role: Evaluate new antibodies for tissue applications.
DOD (J Chan)
5%
Prostate Microenvironment & Prostate Cancer Progression
The goal is to conduct a novel epidemiologic study of the prostate nutritional microenvironment and its
associations with prostate cancer aggressiveness, gene expression, and genomic copy number in 375 prostate
cancer patients.
Role: Central Pathology review
R01 (Kurhanewicz)
10%
NIH
Hyperpolarized 13C MR - Improved Prostate Cancer Risk Stratification
Radiologic-Pathologic Correlation study to determine if new imaging approach can recognize prostate cancer.
Role: Pathology review and direct optimized specimen collection
R21 (Westphalen)
NIH
Pre-biopsy MR imaging of the prostate in men with elevated PSA
Conventional radiologic pathologic correlation studies of the multiparametric MRI examination.
Role: Central Pathology review
PAST
R01 CA1039434-01A2 (Vigneron)
09/01/06 - 02/28/12
13
3%
3%
Jeff Simko
NIH/NCI
$177,500
Molecular Imaging of Prostate Cancer
The goal of this project is to evaluate the use of new single-shot fast-spin echo diffusion sequence for
improved assessment of prostate cancer extent in patient studies at 1.5T .
Role: Pathology review and direct optimized specimen collection.
R01 CA089715-06A2 (Albertson)
06/01/08 - 07/31/13
1%
NIH/NCI
$330,371
Bladder Cancer Risk and Genomic Alterations
The goal of this project is to define genomic alterations that are associated with increasing stage of bladder
cancers. Tissue collections with known treatment and follow-up will be used to define prognostic and
predictive utility.
Role: Co-Investigator
U01 (Febbo)
5%
NIH
Validation of Prognostic and Predictive Signatures in Lethal Prostate Cancer
The goal is to validate (or not) some of the recently recognized possible biomarkers that help to identify those
tumors that have the highest likelihood of escaping current therapeutic strategies.
Role: Central Pathology review and histologic correlation with molecular findings.
RTOG Tissue Bank/Biospecimen Repository (Waldman)
01/01/08 - 06/30/10
30%
Radiation Therapy Oncology Group
RTOG Tissue Bank/Biospecimen Repository: Manage this national cooperative group tissue bank and interact
with the RTOG investigators on collaborative translational research projects.
Role: Co-Investigator (Associate Director)
R01 CA118919 (Liu)
03/01/06 - 02/28/11
4%
NIH
$250,000
Mapping a Clinically Significant Internalizing Tumor Epitope Space
The goal is to develop antibody library-based methods which promote efficient identification of clinically
relevant tumor specific cell surface antigens, methods which are applicable to the identification of cell typespecific lineage markers in general.
Role: Evaluate new antibodies for tissue applications.
RO1 CA106947-01A2 (Chan)
05/01/07 - 08/31/10
5%
NIH
$279.000
Prostate Microenvironment & Prostate Cancer Progression
The goal is to conduct a novel epidemiologic study of the prostate nutritional microenvironment and its
associations with prostate cancer aggressiveness, gene expression, and genomic copy number in 375 prostate
cancer patients.
Role: Central Pathology review
NIH (Waldman)
04/01/08 - 03/31/10
5%
NIH
$1,932,304
Predictive Markers in Metastatic Renal Cancer
The goals of this project are understand the biological mechanisms underlying the risk factors for kidney and
bladder cancer phenotypes and identify global genetic, epigenetic, RNA expression, and proteomic alterations
in tumors and place them in specific biological pathways that are essential to development, progression,
response to therapy, and maintenance of subtypes of bladder and kidney cancers.
Role: Co-investigator (Central Pathology review and histologic correlation with molecular findings).
14
Jeff Simko
R01 CA102751 (Kurhanewicz)
03/01/05 - 08/31/06
5%
NIH/NCI
$294,530
MR Based Molecular Imaging of Prostate Cancer
The goal of this project is to correlate pathologic findings, expression profiles and genetic changes to
spectroscopic (chemical) findings determined by Magnetic Resonance Spectroscopic Imaging (MRSI).
Role: Pathology review and direct optimized specimen collection
R01 CA101042 (Haqq)
06/10/03 - 05/31/08
NIH/NCI
$225,500
Molecular Effects of Nutrition Supplements in Prostate Trials
Clinical trial of using microarrays to discover the transcriptome response to diet for prostate cancer.
Role: Pathology review and direct optimized specimen collection
5%
R01 CA102600 (Waldman)
08/01/03 - 05/31/08
10%
NIH/NCI
$15,977
Renal Cancer Genomic Alterations and Environmental Risk
The overall design of this study is to characterize over 700 renal tumors by array CGH to define genomic
alterations and their associations with clinical variables, and with exposure, and genetic risk factors
Role: Co-investigator (Central Pathology review and histologic correlation with molecular findings).
Mount Zion Health Fund (Simko)
UCSF Comprehensive Cancer Center
Magnetic Resonance Profiles (NMR) of Renal Tumors
Role: PI
01/01/07 - 02/28/09
$15,000
NIH (Coakley)
04/01/04 - 03/31/09
1%
NIH/NCI
$91,000
ACRIN 6659: MR Imaging and MR Spectroscopic Imaging of Prostate Cancer Prior to Radical
Prostatectomy: A Prospective Multi-Institutional Clinicopathological Study. The goal of this project is to
compare the diagnostic accuracy of MRI alone compared to MRI combined with MRSI for the localization of
prostate cancer in patients who are scheduled to have radical prostatectomy surgery.
Role: Pathology review and direct optimized specimen collection
ACS (Noworolski)
01/01/05 - 12/31/09
5%
American Cancer Society
$117,099
“Dynamic Contrast-Enhanced MRI of Prostate Cancer.” Acquisition and post-processing of dynamic contrastenhanced MRI (DCE MRI) of prostate will be developed and compared to MRI, MR spectroscopic imaging
(MRSI) and histopathological analysis of prostate tissue to determine possible value for clinical applications.
Role: Pathology review and direct optimized specimen collection
RSG-05-241-01-CCE (Swanson)
07/01/05 - 06/30/09
5%
American Cancer Society
$149,491
Metabolic Profiles of Residual/Recurrent Prostate Cancer After Therapy
The goal of this project is to determine whether the levels of specific choline and ethanolamine containing
compounds correlate with the presence of residual or recurrent prostate cancer following hormone deprivation
and radiation therapies.
Role: Pathology review and direct optimized specimen collection
P50 CA89520 (Shuman)
NIH/NCI – Bridge Funding
Prostate SPORE-Core B: Tissue Core (PI: Simko, Jeffry)
15
07/01/08 - 06/30/09
$21,537
10%
Jeff Simko
Project 4: Antibody Gene Diversity Libraries and Phage Display to Generate Recombinant Human Antibodies
for Prostate Cancer Therapy
The major goals are to 1) generate new phage antibody libraries; 2) select antibodies which bind specifically to
prostate cancer cells; and 3) use the antibodies to isolate novel prostate cancer surface antigens.
Role: Co-PI (Tissue Core Director)
P50 CA89520 (Shuman)
10/01/00-06/30/06
55%
NIH/NCI
Prostate SPORE-Core B: Tissue Core (PI: Simko, Jeffry)
Project 4: Antibody Gene Diversity Libraries and Phage Display to Generate Recombinant Human Antibodies
for Prostate Cancer Therapy
The major goals are to 1) generate new phage antibody libraries; 2) select antibodies which bind specifically to
prostate cancer cells; and 3) use the antibodies to isolate novel prostate cancer surface antigengs.
Role: Co-PI (Tissue Core Director)
PEER REVIEWED PUBLICATIONS:
1. J.P. Simko and G Oehrlein, "Reactive Ion Etching of Silicon and Silicon Dioxide in CF4 Plasmas containing
Hydrogen or C2F4 additives", J. of the Electrochemical Society 138, 2748 (1991).
2. J.P. Simko, G.S. Oehrlein and T.M. Mayer, "Removal of Fluorocarbon Residues on CF4/H2 Reactive Ion
Etched Silicon Surfaces using a Hydrogen Plasma", J. of the Electrochemical Society 138, 277 (1991).
3. Y.Z. Hu, K.A. Conrad, M. Li, J.W. Andrews, J.P. Simko and E.A. Irene, "Studies of Hydrogen Ion Beam
Cleaning of Silicon Dioxide from Silicon using in-situ Spectroscopic Ellipsometry and X-ray Photo-electron
Spectroscopy", Applied Physics Letters 58, 589 (1991).
4. J.P. Simko, T. Meguro, S. Iwai, K. Ozasa, A. Hirata, Y. Aoyagi and T. Sugano, "Direct Observation of Selflimiting Gallium Deposition on Gallium Arsenide during Laser-atomic Layer Epitaxial Processing", Japan
Journal of Applied Physics Letters 39, L1518 (1992).
5. J.P. Simko, T. Meguro, S. Iwai, K. Ozasa, Y. Aoyagi and T. Sugano, "Surface Photo-absorption Study of
the Laser-assisted Atomic Layer Epitaxial Growth Process of Gallium Arsenide", Proceedings of the Second
International Symposium on Atomic Layer Epitaxy, June 3-6, 1992, Raleigh, North Carolina, Thin Solid
Films 225, 40 (1993).
6. J.P. Simko, A. Caliendo, K. Hogle, J. Versalovic, “Detection of Herpes Simplex Virus DNA in
Cerebrospinal Fluid specimens by PCR: Correlation with Clinical Presentation and Patient History,”
Clin. Infect. Dis. 35(4): 414-9 (2002).
7. Paris PL, Andaya A, Fridlyand J, Jain AN, Weinberg V, Kowbel D, Brebner JH, Simko J, Watson JE, Volik
S, Albertson DG, Pinkel D, Alers JC, van der Kwast TH, Vissers KJ, Schroder FH, Wildhagen MF, Febbo
PG, Chinnaiyan AM, Pienta KJ, Carroll PR, Rubin MA, Collins C, van Dekken H., "Whole genome
scanning identifies genotypes associated with recurrence and metastasis in prostate tumors," Hum Mol
Genet. 13(13): 1303-13 (2004).
8. Watson JE, Doggett NA, Albertson DG, Andaya A, Chinnaiyan A, Van Dekken H, Ginzinger D, Haqq C,
James K, Kamkar S, Kowbel D, Pinkel D, Schmitt L, Simko JP, Volik S, Weinberg VK, Paris PL, Collins
C., “Integration of high-resolution array comparative genomic hybridization analysis of chromosome 16q
with expression array data refines common regions of loss at 16q23-qter and identifies underlying candidate
tumor suppressor genes in prostate cancer. Oncogene 23(19):3487-94 (2004).
16
Jeff Simko
9. Watson JE, Kamkar S, James K, Kowbel D, Andaya A, Paris PL, Simko J, Carroll P, McAlhany S, Rowley
D, Collins C, "Molecular analysis of WFDC1/ps20 gene in prostate cancer," Prostate 61(2): 192-9 (2004).
10. Retz MM, Sidhu SS, Blaveri E, Kerr SC, Dolganov GM, Lehmann J, Carroll P, Simko J, Waldman
FM, Basbaum C, "CXCR4 expression reflects tumor progression and regulates motility of bladder
cancer cells," Int J Cancer 114(2): 182-9 (2005).
11. E Blaveri, JP Simko, JE Korkola, JL Brewer, F Baehner, K Mehta, S DeVries, T Koppie, S Pejavar, P
Carroll and F Waldman, "GENE EXPRESSION PATTERNS IDENTIFY BLADDER CANCER SUBTYPES
AND PREDICT OUTCOME," Clin Cancer Res 11(11): 4044-55 (2005).
12. Master VA, Chi T, Simko JP, Weinberg V, Carroll PR, "The independent impact of extended pattern biopsy
on prostate cancer stage migration," J Urol 174(5): 1789-93 (2005).
13. Blaveri E, Brewer JL, Roydasgupta R, Fridlyand J, DeVries S, Koppie T, Pejavar S, Mehta K, Carroll P,
Simko JP, Waldman FM, "Bladder cancer stage and outcome by array-based comparative genomic
hybridization," Clin Cancer Res 11(19 Pt 1): 7012-22 (2005).
14. WA Ricke, K Ishii, EA Ricke, JP Simko, YZ Wang, SW Hayward, and FR Cunha, "Steroid Hormones
Stimulate Human Prostate Cancer Progression and Metastasis,” Int J Cancer 118(9): 2123-31 (2006).
15. Paris P, Weinberg V, Simko J, Andaya A, Albo G, Rubin M, Carroll P, Collins C, "Preliminary
Validation of Prostate Cancer Metastatic Risk Biomarkers," Int. J. Biomarkers 20(3): 141-45 (2005).
16. Hom JJ, Coakley FV, Simko JP, Qayyum A, Lu Y, Schmitt L, Carroll PR, Kurhanewicz J, "Prostate
Cancer: Endorectal MR Imaging and MR Spectroscopic Imaging--Distinction of True-Positive Results from
Chance-detected Lesions," Radiology 238(1): 192-9 (2006).
17. Rini BI, Weinberg V, Dunlap S, Elchinoff A, Yu N, Bok R, Simko J, Small EJ, "Maximal COX-2
immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell
carcinoma," Cancer 106(3): 566-75 (2006).
18. Sanchez-Mejia RO, Ojemann SG, Simko J, Chaudhary UB, Levy J, Lawton MT, "Sacral epithelioid
angiosarcoma associated with a bleeding diathesis and spinal epidural hematoma: case report," J Neurosurg
Spine 4(3): 246-50 (2006).
19. A M De Marzo , E A Platz , J I Epstein , T Ali , A Billis, T Y Chan , L Cheng, M Datta, L Egevad, D
Ertoy-Baydar , X Farre , S W Fine , K A Iczkowski, M Ittmann, B S Knudsen, M Loda, A Lopez-Beltran, C
Magi-Galluzzi, G Mikuz , R Montironi, E Pikarsky, G Pizov, M A Rubin, H Samaratunga, T Sebo, I A
Sesterhenn, RB Shah, S Signoretti, J Simko ,G Thomas, P Troncoso, T Tsuzuki, G JLH van Leenders, XJ
Yang, M Zhou, W D Figg, A Hoque and M S Lucia, "A Working Group Classification of Focal Prostate
Atrophy Lesions," Am. J. Surg. Pathol. 30(10): 1281-91 (2006).
20. M Swanson, A Zektzer, ZL Tabatabai, J Simko, S Jarso, K Keshari, L Schmitt, P Carroll, K Shinohara, D
Vigneron, and J Kurhanewicz, "Quantitative Analysis of Prostate Metabolites using 1H HR-MAS
Spectroscopy," Mag Res Med 55(6): 1257-64 (2006).
21. B. Rini, E. Jaeger, N. Sein, K. Fong, K. Chew, J. Simko and F. Waldman, “Clinical Response to VEGFTargeted Therapy in Metastatic Renal Cell Carcinoma: Impact of Patient Characteristics and VHL Gene
Status,” Br. J. Urol. Int. 98(4): 756-62 (2006).
17
Jeff Simko
22. Ruan W, Sassoon A, An F, Simko JP, Liu B, "Identification of clinically significant tumor antigens by
selecting phage antibody library on tumor cells in situ using laser capture microdissection," Mol Cell
Proteomics 5(12) 2364-73 (2006).
23. PL Paris, MD Hofer, G Albo, R Kuefer, JE Gschwend, RE Hautmann, J Fridyland, JP Simko, PR Carroll,
MA Rubin, and C Collins,”Genomic profiling of hormone naïve lymph node metastases in patients with
prostate cancer," Neoplasia 8(12): 1083-9 (2006).
24. Ryan C, Haqq C, Simko J, Chan J, Weinberg V, Goldfine I, “Expression of insulin-like growth factor
receptor in local and metastatic prostate cancer,” Uro. Oncol 25(2): 134-40 (2007).
25. Hom JJ, Coakley FV, Simko JP, Lu Y, Qayyum A, Westphalen A, Schmitt L, Carroll PR, Kurhanewicz J.
“High-grade prostatic intraepithelial neoplasia in patients with prostate cancer: MR and MR spectroscopic
imaging features,” Radiology 242(2): 483-9 (2007).
26. W. Nau, E. Bass, C. Diederich, W. Ferrier, J. Simko, R. Pelligrino, J. Sutton and R. Shu, “Intradiscal
thermal Therapy Using Interstitial Unltrasound: An In Vivo Feasibility Study in Ovine Cervical Spine,”
Spine 32(5): 503-11 (2007).
27. Mosquera JM, Perner S, Demichelis F, Kim R, Hofer MD, Mertz KD, Paris PL, Simko J, Collins C, Bismar
TA, Chinnaiyan AM, Rubin MA, "Morphological features of TMPRSS2-ERG gene fusion prostate cancer,"
J Pathol 212(1): 91-101 (2007).
28. Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan
AM, De Marzo AM, Rubin MA, "TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event
Associated With Invasion," Am J Surg Pathol 31(6): 882-888 (2007).
29. Jancelewicz T, Simko J, Lee H, "Obstructing ileal duplication cyst infected with Salmonella in a 2-year-old
boy: a case report and review of the literature," J Pediatr Surg 42(5): E19-21 (2007).
30. Liu B, Conrad F, Roth A, Drummond DC, Simko JP, Marks JD, "Recombinant full-length human IgG1s
targeting hormone-refractory prostate cancer," J Mol Med 85(10): 1113-23 (2007).
31. Westphalen AC, Coakley FV, Qayyum A, Swanson M, Simko JP, Lu Y, Zhao S, Carroll PR, Yeh BM,
Kurhanewicz J, "Peripheral zone prostate cancer: accuracy of different interpretative approaches with MR
and MR spectroscopic imaging," Radiology 246(1): 177-84 (2008).
32. D. Ornish, M Magbanua, G Weidner, V Weinberg, C Kemp, C Green, M Mattie, R Marlin, J Simko, K
Shinohara, C Haqq and P Carroll, "Changes in prostate Gene expresssion in men undergoing an intensive
nutrition and lifestyle intervention," PNAS 105(24): 8369-74 (2008).
33. Swanson MG, Keshari KR, Tabatabai ZL, Simko JP, Shinohara K, Carroll PR, Zektzer AS, Kurhanewicz J,
"Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HRMAS total correlation spectroscopy," Magn Reson Med 60(1): 33-40 (2008).
34. Mosquera JM, Perner S, Genega EM, Sanda M, Hofer MD, Mertz KD, Paris PL, Simko J, Bismar TA,
Ayala G, Shah RB, Loda M, Rubin MA, "Characterization of TMPRSS2-ERG fusion high-grade prostatic
intraepithelial neoplasia and potential clinical implications," Clin Cancer Res 14(11): 3380-5 (2008).
35. Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N, Simko J,
Golshayan AR, Sercia L, Zhou M, Waldman FM, Rini BI, Bukowski RM, Ganapathi R, "von Hippel-Lindau
gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal
cell carcinoma," J Urol 180(3): 860-5 (2008).
18
Jeff Simko
36. Tessem MB, Swanson MG, Keshari KR, Albers MJ, Joun D, Tabatabai ZL, Simko JP, Shinohara K, Nelson
SJ, Vigneron DB, Gribbestad IS, Kurhanewicz J, "Evaluation of lactate and alanine as metabolic biomarkers
of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues," Magn Reson Med 60(3): 510-6
(2008).
37. Paris PL, Sridharan S, Hittelman AB, Kobayashi Y, Perner S, Huang G, Simko J, Carroll P, Rubin MA,
Collins C, "An oncogenic role for the multiple endocrine neoplasia type 1 gene in prostate cancer," Prostate
Cancer Prostatic Dis. 12(2): 184-91 (2009).
38. C Crane, A Panner, JC Murray, SP Wilson, H Xu, L Chen, JP Simko, FM Waldman, RO Pieper and AT
Parsa, "P(i)3 kinase is associated wit a mechanism of immunoresistance in breast and prostate cancer,"
Oncogene 28(2): 306-12 (2009).
39. Paris PL, Kobayashi Y, Zhao Q, Zeng W, Sridharan S, Fan T, Adler HL, Yera ER, Zarrabi MH, Zucker S,
Simko J, Chen WT, Rosenberg J, "Functional phenotyping and genotyping of circulating tumor cells from
patients with castration resistant prostate cancer," Cancer Lett 277(2): 164-73 (2009).
40. Torabian SZ, de Semir D, Nosrati M, Bagheri S, Dar AA, Fong S, Liu Y, Federman S, Simko J, Haqq C,
Debs RJ, Kashani-Sabet M, "Ribozyme-mediated targeting of IkappaBgamma inhibits melanoma invasion
and metastasis," Am J Pathol 174(3): 1009-16 (2009).
41. Conti SL, Dall'era M, Fradet V, Cowan JE, Simko J, Carroll PR, "Pathological outcomes of candidates for
active surveillance of prostate cancer," J Urol 181(4): 1628-33 (2009).
42. Kashani-Sabet M, Rangel J, Torabian S, Nosrati M, Simko J, Jablons DM, Moore DH, Haqq C, Miller JR
3rd, Sagebiel RW, "A multi-marker assay to distinguish malignant melanomas from benign nevi," Proc Natl
Acad Sci U S A. 106(15): 6268-72 (2009).
43. Hou Y, DeVoss J, Dao V, Kwek S, Simko JP, McNeel DG, Anderson MS, Fong L, "An aberrant prostate
antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in
humans," J Clin Invest 119(7): 2031-41 (2009).
44. Westphalen AC, Coakley FV, Kurhanewicz J, Reed G, Wang ZJ, Simko JP, "Mucinous adenocarcinoma of
the prostate: MRI and MR spectroscopy features," Am J Roentgenol 193(3): W238-43 (2009).
45. Kashani-Sabet M, Venna S, Nosrati M, Rangel J, Sucker A, Egberts F, Baehner FL, Simko J, Leong SP,
Haqq C, Hauschild A, Schadendorf D, Miller JR 3rd, Sagebiel RW, "A multimarker prognostic assay for
primary cutaneous melanoma," Clin Cancer Res 15(22): 6987-92 (2009).
46. Paris PL, Weinberg V, Albo G, Roy R, Burke C, Simko J, Carroll P, Collins C, "A group of genome-based
biomarkers that add to a Kattan nomogram for predicting progression in men with high-risk prostate cancer,"
Clin Cancer Res 16(1): 195-202 (2010).
47. Santos CF, Kurhanewicz J, Tabatabai ZL, Simko JP, Keshari KR, Gbegnon A, Santos RD, Federman S,
Shinohara K, Carroll PR, Haqq CM, Swanson MG, "Metabolic, pathologic, and genetic analysis of prostate
tissues: quantitative evaluation of histopathologic and mRNA integrity after HR-MAS spectroscopy," NMR
Biomed 23(4): 391-8 (2010).
48. Vagefi PA, Klein I, Gelb B, Hameed B, Moff SL, Simko JP, Fix OK, Eilers H, Feiner JR, Ascher NL,
Freise CE, Bass NM, "Emergent Orthotopic Liver Transplantation for Hemorrhage from a Giant Cavernous
Hepatic Hemangioma: Case Report and Review," J Gastrointest Surg 15(1): 209-14 (2011).
19
Jeff Simko
49. Dall'era MA, Cowan JE, Simko J, Shinohara K, Davies B, Konety BR, Meng MV, Perez N, Greene K,
Carroll PR, "Surgical management after active surveillance for low-risk prostate cancer: pathological
outcomes compared with men undergoing immediate treatment," BJU Int 107(8): 1232-7 (2011).
50. Moltzahn F, Olshen AB, Baehner L, Peek A, Fong L, Stöppler H, Simko J, Hilton JF, Carroll P, Blelloch R,
"Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the
sera of prostate cancer patients," Cancer Res 71(2): 550-60 (2011).
51. Chan JM, Weinberg V, Magbanua MJ, Sosa E, Simko J, Shinohara K, Federman S, Mattie M, HughesFulford M, Haqq C, Carroll PR, "Nutritional supplements, COX-2 and IGF-1 expression in men on active
surveillance for prostate cancer," Cancer Causes Control 22(1): 141-50 (2011).
52. Whitson JM, Porten SP, Hilton JF, Cowan JE, Perez N, Cooperberg MR, Greene KL, Meng MV, Simko JP,
Shinohara K, Carroll PR, "The relationship between prostate specific antigen change and biopsy progression
in patients on active surveillance for prostate cancer," J Urol 185(5): 1656-60 (2011).
53. Whitson JM, Porten SP, Cowan JE, Simko JP, Cooperberg MR, Carroll PR, "Factors associated with
downgrading in patients with high grade prostate cancer," Urol Oncol. 2011 Apr 7. [Epub ahead of print]
54. McKenney JK, Simko J, Bonham M, True LD, Troyer D, Hawley S, Newcomb LF, Fazli L, Kunju LP,
Nicolas MM, Vakar-Lopez F, Zhang X, Carroll PR, Brooks JD; Canary/Early Detection Research Network
Prostate Active Surveillance Study Investigators, "The potential impact of reproducibility of Gleason grading
in men with early stage prostate cancer managed by active surveillance: a multi-institutional study," J Urol
186(2): 465-9 (2011).
55. Jalas JR, Vemula S, Bezrookove V, Leboit PE, Simko JP, Bastian BC, "Metastatic melanoma with striking
adenocarcinomatous differentiation illustrating phenotypic plasticity in melanoma," Am J Surg Pathol 35(9):
1413-8 (2011).
56. Magbanua MJ, Roy R, Sosa EV, Weinberg V, Federman S, Mattie MD, Hughes-Fulford M, Simko J,
Shinohara K, Haqq CM, Carroll PR, Chan JM, "Gene expression and biological pathways in tissue of men
with prostate cancer in a randomized clinical trial of lycopene and fish oil supplementation," PLoS One.
2011;6(9):e24004. Epub 2011 Sep 1.
57. Ray M, Hostetter DR, Loeb CR, Simko J, Craik CS, "Inhibition of Granzyme B by PI-9 protects prostate
cancer cells from apoptosis," Prostate. 2012 Jun 1;72(8):846-55. doi: 10.1002/pros.21486. Epub 2011 Sep
14.
58. Chen L, Hong C, Chen EC, Yee SW, Xu L, Almof EU, Wen C, Fujii K, Johns SJ, Stryke D, Ferrin TE,
Simko J, Chen X, Costello JF, Giacomini KM, "Genetic and epigenetic regulation of the organic cation
transporter 3, SLC22A3," Pharmacogenomics J. 2012 Jan 10. doi: 10.1038/tpj.2011.60. [Epub ahead of
print]
59. Magbanua MJ, Sosa EV, Scott JH, Simko J, Collins C, Pinkel D, Ryan CJ, Park JW, "Isolation and genomic
analysis of circulating tumor cells from castration resistant metastatic prostate cancer," BMC Cancer. 2012
Feb 28;12(1):78. [Epub ahead of print]
60. Busch S, Hatridge M, Mößle M, Myers W, Wong T, Mück M, Chew K, Kuchinsky K, Simko J, Clarke J,
"Measurements of T(1) -relaxation in ex vivo prostate tissue at 132 μT," Magn Reson Med. 2012
Apr;67(4):1138-45. doi: 10.1002/mrm.24177. Epub 2012 Jan 31.
61. Ausborn NL, Le QT, Bradley JD, Choy H, Dicker AP, Saha D, Simko J, Story MD, Torossian A, Lu B,
"Molecular Profiling to Optimize Treatment in Non-Small Cell Lung Cancer: A Review of Potential
20
Jeff Simko
Molecular Targets for Radiation Therapy by the Translational Research Program of the Radiation Therapy
Oncology Group," Int J Radiat Oncol Biol Phys. 2012 Apr 18. [Epub ahead of print]
62. Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI, "Do Adenocarcinomas of the
Prostate With Gleason Score (GS)≤6 Have the Potential to Metastasize to Lymph Nodes?," Am J Surg
Pathol. 2012 Apr 22. [Epub ahead of print]
63. Hayes GM, Simko J, Holochwost D, Kuchinsky K, Busch R, Misell L, Murphy EJ, Carroll PR, Chan JM,
Shinohara K, Hellerstein MK, "Regional Cell Proliferation in Microdissected Human Prostate Specimens
After Heavy Water-Labeling in vivo: Correlation With Prostate Epithelial Cells Isolated From Seminal
Fluid," Clin Cancer Res. 2012 May 2. [Epub ahead of print]
64. Kwek SS, Dao V, Roy R, Hou Y, Alajajian D, Simko JP, Small EJ, Fong L, "Diversity of antigen-specific
responses induced in vivo with ctla-4 blockade in prostate cancer patients, J Immunol 189(7): 3759-66
(2012).
65. Cooperberg MR, Simko JP, Cowan JE, Reid JE, Djalilvand A, Bhatnagar S, Gutin A, Lanchbury JS,
Swanson GP, Stone S, Carroll PR, "Validation of a cell-cycle progression gene panel to improve risk
stratification in a contemporary prostatectomy cohort," J Clin Oncol 31(11): 1428-34 (2013).
66. Hawley S, Fazli L, McKenney JK, Simko J, Troyer D, Nicolas M, Newcomb LF, Cowan JE, Crouch L,
Ferrari M, Hernandez J, Hurtado-Coll A, Kuchinsky K, Liew J, Mendez-Meza R, Smith E, Tenggara I,
Zhang X, Carroll PR, Chan JM, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, Feng Z, True LD,
Brooks JD, "A model for the design and construction of a resource for the validation of prognostic prostate
cancer biomarkers: the Canary Prostate Cancer Tissue Microarray," Adv Anat Pathol 20(1): 39-44 (2013).
67. Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK,
Donner DB, Settleman J, Shokat KM, Warren RS, "Incomplete inhibition of phosphorylation of 4E-BP1 as a
mechanism of primary resistance to ATP-competitive mTOR inhibitors," Oncogene. 2013 Apr 1. doi:
10.1038/onc.2013.92. [Epub ahead of print]
68. Odisho AY, Washington SL 3rd, Meng MV, Cowan JE, Simko JP, Carroll PR, "Benign Prostate Glandular
Tissue at Radical Prostatectomy Surgical Margins," Urology 82(1) 154-9 (2013).
69. Stieglitz E, Hsiang MS, Simko JP, Hirose S, Goldsby RE, "Pulmonary Coccidiomycosis Masquerading as
Refractory Metastatic Ewing Sarcoma," J Pediatr Hematol Oncol 36(1): E57-60 (2014).
70. O Starobinets, R Guo, JP Simko, MD, PhD, K Kuchinsky, J Kurhanewicz, PR Carroll, KL Greene, SM
Noworolski, "Semi-automatic registration of digital histopathology images to in-vivo MR images in molded
and unmolded prostates," J Magn Reson Imaging 39(5): 1223-9 (2014).
71. Van Allen EM, Foye A, Wagle N, Kim W, Carter SL, McKenna A, Simko JP, Garraway LA, Febbo PG,
"Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy," Prostate Cancer
Prostatic Dis. 2013 Dec 24. doi: 10.1038/pcan.2013.37. [Epub ahead of print] PMID: 24366412
72. Anwar M, Westphalen AC, Jung AJ, Noworolski SM, Simko JP, Kurhanewicz J, Roach M 3rd, Carroll PR,
Coakley FV, "Role of endorectal MR imaging and MR spectroscopic imaging in defining treatable
intraprostatic tumor foci in prostate cancer: quantitative analysis of imaging contour compared to wholemount histopathology," Radiother Oncol 110(2): 303-8 (2014).
73. Hosgood HD 3rd, Pao W, Rothman N, Hu W, Pan YH, Kuchinsky K, Jones KD, Xu J, Vermeulen R, Simko
J, Lan Q, "Driver mutations among never smoking female lung cancer tissues in China identify unique
21
Jeff Simko
EGFR and KRAS mutation pattern associated with household coal burning," Respir Med 107(11): 1755-62
(2013).
74. Magbanua MJ, Richman EL, Sosa EV, Jones LW, Simko J, Shinohara K, Haqq CM, Carroll PR, Chan JM,
"Physical activity and prostate gene expression in men with low-risk prostate cancer," Cancer Causes
Control 25(4): 515-23 (2014).
75. Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan
JE, Tsiatis AC, Cherbavaz DB, Pelham RJ, Tenggara-Hunter I, Baehner FL, Knezevic D, Febbo PG, Shak S,
Kattan MW, Lee M, Carroll PR, "A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context
of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling," Eur Urol. 2014 May
16. pii: S0302-2838(14)00414-X. doi: 10.1016/j.eururo.2014.05.004. [Epub ahead of print] PMID:
24836057
76. Wang SY, Shiboski S, Belair CD, Cooperberg MR, Simko JP, Stoppler H, Cowan J, Carroll PR, Blelloch R,
"miR-19, miR-345, miR-519c-5p Serum Levels Predict Adverse Pathology in Prostate Cancer Patients
Eligible for Active Surveillance," PLoS One 9(6):e98597 (2014). PMID: 24893170
77. Jung AJ, Westphalen AC, Kurhanewicz J, Wang ZJ, Carroll PR, Simko JP, Coakley FV, "Clinical utility of
endorectal MRI-guided prostate biopsy: preliminary experience, "J Magn Reson Imaging 40(2): 314-23
(2014). PMID: 24924999
78. Walker EJ, Simko JP, Ko AH, "Hepatitis B viral reactivation secondary to imatinib treatment in a patient
with gastrointestinal stromal tumor," Anticancer Res 34(7): 3629-34 (2014). PMID: 24982379
79. Siegel EM, Eschrich S, Winter K, Riggs B, Berglund A, Ajidahun A, Simko J, Moughan J, Ajani J,
Magliocco A, Elahi A, Hoffe S, Shibata D, "Epigenomic Characterization of Locally Advanced Anal
Cancer: A Radiation Therapy Oncology Group 98-11 Specimen Study," Dis Colon Rectum 57(8): 941-957
(2014). PMID: 25003289
80. Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, Amling CL, Stephenson RA, Simko J, Sheikh
NA, Sims RB, Frohlich MW, Small EJ, "Activated lymphocyte recruitment into the tumor
microenvironment following preoperative sipuleucel-T for localized prostate cancer," J Natl Cancer Inst.
2014 Sep 24;106(11). PMID:25255802
81. Welty CJ, Cowan JE, Nguyen H, Shinohara K, Perez N, Greene KL, Chan JM, Meng MV, Simko JP,
Cooperberg MR, Carroll PR, "Extended Follow-Up and Risk Factors for Disease Reclassification from a
Large Active Surveillance Cohort for Localized Prostate Cancer," J Urol. 2014 Sep 24.[Epub ahead of print]
PMID:25261803
82. Raleigh DR, Hsu IC, Braunstein S, Chang AJ, Simko JP, Roach M 3rd, "Bladder wall recurrence of prostate
cancer after high-dose-rate brachytherapy," Brachytherapy 14(2): 185-8 (2015). PMID: 25533416
83. Walker EJ, Simko JP, Nakakura EK, Ko AH, "A patient with cholangiocarcinoma demonstrating pathologic
complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract cancer," J
Gastrointest Oncol. 2014 Dec;5(6):E88-95. doi: 10.3978/j.issn.2078-6891.2014.051.
84. Hope TA, Aggarwal R, Simko JP, VanBrocklin HF, Ryan CJ, "Somatostatin imaging of neuroendocrinedifferentiated prostate cancer," Clin Nucl Med 40(6): 540-1 (2015). PMID: 25783510
85. Troyer DA, Jamaspishvili T, Wei W, Feng Z, Good J, Hawley S, Fazli L, McKenney JK, Simko J, HurtadoColl A, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Brooks JD, Squire
JA, "A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and
22
Jeff Simko
extracapsular extension in localized prostate cancer," Prostate. 2015 May 4. doi: 10.1002/pros.23003. [Epub
ahead of print], PMID: 25939393
86. Jalloh M, Leapman MS, Cowan JE, Shinohara K, Greene KL, Roach M III, Chang AJ, Chan JM, Simko JP,
Carroll PR, "Patterns of Local Failure Following Radiation Therapy for Prostate Cancer," J Urol (2015).
(epub ahead of print) 10.1016/j.juro.2015.04.111.
87. Brooks JD, Wei W, Hawley S, Auman H, Newcomb L, Boyer H, Fazli L, Simko J, Hurtado-Coll A, Troyer
DA, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, McKenney JK,
"Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a
Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients," PLoS One 10(7): e0132343 (2015).
PMID: 26172920
88. Belair CD, Paikari A, Moltzahn F, Shenoy A, Yau C, Dall'Era M, Simko J, Benz C, Blelloch R, "DGCR8 is
essential for tumor progression following PTEN loss in the prostate," EMBO Rep. 2015 Jul 23. pii:
e201439925. [Epub ahead of print] PMID: 26206718
NON-PEER REVIEWED PUBLICATIONS AND OTHER CREATIVE ACTIVITIES:
1.
S.J. DeArmond, J.P. Simko and D.A. Gaskin, “The Molecular and Genetic Basis of Neurodegenerative
Diseases,” in Modern Surgical Pathology, N. Weidner, Ed. (W.B. Saunders, New York, 2003) pp. 21212153.
2.
JP Simko and FM Waldman, “Molecular and Special Techniques,” in Immunomicroscopy: A Diagnostic
Tool for the Surgical Pathologist, 3rd Edition, C. Taylor, R. Cote Eds. (Elsevier, St. Louis, 2006).
3.
JP Simko, Editorial for H. Eyas, et al., “Tertiary Gleason Pattern 5 is a Powerful Predictor of Biochemical
Relapse in Patients with Gleason Score 7 Prostatic Adenocarcinoma,” J. Urol. (2006).
4.
BM Ljung and JP Simko, “Issues and Methodologies for Sampling Breast Cancers for Molecular Studies
and Diagnosis: Lessons from a Pathologist’s Bench,” in Seminars in Breast Disease, A. Thor Ed.
(Elsevier, St. Louis, 2007).
5.
S.J. DeArmond, TA Tousseyn, J.P. Simko and D.A. Gaskin, “The Molecular and Genetic Basis of
Neurodegenerative Diseases” in Modern Surgical Pathology Second Edition, N. Weidner, Ed. (W.B.
Saunders, New York, 2009) pp. 2039-2068.
6.
Simko JP, "Letter to the editor," J Urol 190(6): 2066-7 (2013).
RESEARCH PROGRAM
My major research interests at this time generally involve improving physicians’ diagnostic capabilities for the
management of patients with genitourinary malignancies. These activities are focused in two areas of
diagnostic medicine; radiologic-pathologic correlation studies, and elucidation of diagnostic and prognostic
biomarkers in GU malignancies. These activities are predominantly undertaken within the UCSF
Comprehensive Cancer Center Genitourinary Oncology Program, the former UCSF Prostate SPORE program,
the Canary Foundation Program, the NRG Oncology clinical trials cooperative group, and THE ALLIANCE
(former CALGB) clinical trials cooperative group; all of which are multidisciplinary teams of collaborative
researchers with the common goal of improving the management of patients with genitourinary malignancies
(prostate cancer, bladder cancer and kidney cancer). My primary responsibility in these groups is to provide
the pathology support for these efforts, including overseeing collection, processing and distribution of
23
Jeff Simko
appropriate tissue samples and pathologic specimens to the research projects, consultation and planning of
experiments and grant proposals for most effective use and financing of tissue and pathology resources, and
ultimately use and interpretation of histologic, immunohistologic and in-situ hybridization tissue sections
within the projects themselves. Resident and medical student involvement is encouraged and has occurred.
Radiologic-pathologic correlation studies: UCSF is in a very unique and enviable position due to the vast magnetic
resonance imaging resources here in the Department of Radiology. A number of studies are underway to evaluate
and interpret signals from nuclear magnetic resonance techniques (NMR / MRI), including magnetic resonance
spectroscopic imaging (MRSI), and the new Hyperpolarized Carbon-13 NMR system that enhances the signal of
carbon nuclei 50,000-fold. Use of these techniques for the diagnosis of prostate cancer is currently limited by poor
sensitivity and specificity, due to a lack of understanding of the types of signals generated from specific tissue
types. In our most recent work, we feel that we’ve identified some tissue types that mimic the MRI signals
produced by prostate cancer. Other studies involve correlation of MRSI signals with histologic,
immunohistochemical, expression and genomic findings and patient outcome, in order to determine the relationship
of tumor chemical composition to virulence and metastatic capability. Moving forward, we hope to extend this
understanding to Carbon-13-based imaging, as well as imaging of renal tumors. I’ve also extended collaboration
to the UC Berkeley Physics Department to evaluate the potential of alternative magnetic imaging techniques for
cancer detection using SQUID magnetometers.
Biomarkers: My other focus is within the realm of histologic, genetic and protein expression alterations within
various genitourinary malignancies, with the major goal being to better characterize tumors for improved
diagnostic and prognostic purposes, and also identifying new avenues for potential therapeutic strategies.
Projects underway include histologic evaluation of prostate and renal tumors for national clinical trials (Canary
Foundation, NRG Oncology, ALLIANCE and industrial partners) to correlate with response to therapy,
outcomes, and putative biomarkers. Related to these efforts are attempts to enhance biospecimen collection
and evaluation of biomarker stability and specimen utility for these trials. This extends to efforts to collect
circulating tumor cells, cell free nucleic acids, and matching primary tumor tissue specimens, as well as other
important tumor types ( pancreas and lung carcinomas), where I constructed TMAs of tissues collected from
NRG trials and cohort studies through the NCI Division of Cancer Epidemiology and Genetics, and
contributed over 100 patients to the cancer genome atlas (TCGA) project of NCI. Future plans include
continued participation in clinical trials with NRG Oncology, the Alliance, Canary Foundation and funded
projects with in UCSF Department of Urology related to managing prostate cancer patients on Active
Surveillance (AS) protocols.
Listing of most significant recent publications in last two years:
1. Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J,
Cowan JE, Tsiatis AC, Cherbavaz DB, Pelham RJ, Tenggara-Hunter I, Baehner FL, Knezevic D, Febbo
PG, Shak S, Kattan MW, Lee M, Carroll PR, "A 17-gene Assay to Predict Prostate Cancer Aggressiveness
in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling," Eur
Urol. 2014 May 16. pii: S0302-2838(14)00414-X. doi: 10.1016/j.eururo.2014.05.004. [Epub ahead of
print] PMID: 24836057
I was the Study pathologist on the clinical validation of a biomarker panel that has since entered the
healthcare market in direct competiton with the product developed below, and involved evaluation of over
800 different pathology cases. This accomplishment received national media attention on NBC News and
NY Times.
2. Cooperberg MR, Simko JP, Cowan JE, Reid JE, Djalilvand A, Bhatnagar S, Gutin A, Lanchbury JS,
Swanson GP, Stone S, Carroll PR, "Validation of a cell-cycle progression gene panel to improve risk
stratification in a contemporary prostatectomy cohort," J Clin Oncol 31(11): 1428-34 (2013).
24
Jeff Simko
I was the Study pathologist on the clinical validation of a biomarker panel that has since entered the
healthcare market in direct competition with the product developed above, and involved evaluation of over
500 different pathology cases.
3. Wang SY, Shiboski S, Belair CD, Cooperberg MR, Simko JP, Stoppler H, Cowan J, Carroll PR, Blelloch
R, "miR-19, miR-345, miR-519c-5p Serum Levels Predict Adverse Pathology in Prostate Cancer Patients
Eligible for Active Surveillance," PLoS One 9(6):e98597 (2014). PMID: 24893170
I was the study pathologist for this validation trail that showed for the first time, that a panel of
microRNAs in serum could predict prostate cancer aggressiveness.
4. Van Allen EM, Foye A, Wagle N, Kim W, Carter SL, McKenna A, Simko JP, Garraway LA, Febbo PG,
"Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy," Prostate Cancer
Prostatic Dis. 2013 Dec 24. doi: 10.1038/pcan.2013.37. [Epub ahead of print] PMID: 24366412
This study is the first to show proof of principle, that WGS can be done successfully from bone tissue,
despite harsh chemical treatments and limited tissue specimens. Such a result allows scientists to actively
try to sequence these types of specimens that are critical to furthering our understanding of metastatic
tissue genomic composition. I was responsible for histologic confirmation of all tissue specimens used in
this study.
5. Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, Amling CL, Stephenson RA, Simko J,
Sheikh NA, Sims RB, Frohlich MW, Small EJ, "Activated lymphocyte recruitment into the tumor
microenvironment following preoperative sipuleucel-T for localized prostate cancer," J Natl Cancer Inst.
2014 Sep 24;106(11). PMID:25255802.
This is the first published clinical trial evaluating recruitment of inflammatory cells into tumors, and sets
the groundwork for such evaluations moving forward with the large number of immunotherapies currently
under development for treating cancer in general. I was responsible for collection of all tissue and
biospecimens needed for this study, as well as guidance in the understanding of all histologic and staining
findings that were measured in the tissues.
References to teaching ability:
Nancy M. Joseph , MD, PhD
Assistant Professor Clinical Pathology
Department of Pathology
University of California, San Francisco
2340 Sutter Street, Room S132, Box 0808
San Francisco, CA 94115
Tel: (415) 502-3119
Secondary Tel: (415) 502-3252
Email: Nancy.Joseph@ucsf.edu
Christopher Welty , MD
Clinical Fellow
Department of Urology
University of California, San Francisco
400 Parnassus Ave, UC Clinics Room 635, Box 1695
25
Jeff Simko
San Francisco, CA 94143
Tel: (415) 353-3690
Fax: (415) 885-7443
Email: Weltyc@urology.ucsf.edu
David Solomon , MD, PhD
Clinical Fellow
Department of Pathology
University of California, San Francisco
505 Parnassus Ave, Moffitt Room 580, Box 0102
San Francisco, CA 94143
Tel: (415) 353-1613
Email: David.Solomon@ucsfmedctr.org
Bradley Stohr, MD, PhD
Assistant Professor
Department of Pathology
University of California, San Francisco
513 Parnassus Ave, Room 450D, Box 0502
San Francisco, CA 94143
Tel: (415) 476-6729
Fax: (415) 514-0878
Email: Bradley.Stohr@ucsf.edu
Soo-Jin Cho , MD, PhD
Asstistant Profesor of Clinical Pathology
Department of Pathology
University of California, San Francisco
1825 4th Street, Room M2370, Box 4066
Tel: (415) 885-7586
Fax: (415) 353-1612
Email: Soo-Jin.Cho@ucsf.edu
Han Lee , MD, PhD
Asstistant Profesor of Clinical Pathology
Department of Pathology
University of California, San Francisco
VAMC-113B, Bldg. 2 Room 355A, Box VAMC
Tel: (415) 221-4810 ext. 2615
Fax: (415) 379-5643
Email: Han.Lee@ucsf.edu
Jessica Finn, MD
Assistant Clinical Professor
Medical Director of Histology and Cytology Laboratories
Department of Pathology
26
Jeff Simko
University of California, San Francisco
1600 Divisadero Street, Room B221
San Francisco, CA 94115
Tel: (415) 885-254
Pager: (415) 443-0638
Outside Referees:
Walter J. Curran, Jr., M.D.
Executive Director, Winship Cancer Institute of Emory University
Associate Vice President, Cancer, Woodruff Health Sciences Center
Lawrence W. Davis Chair of Radiation Oncology
Professor
Department of Radiation Oncology
Emory University School of Medicine
Department of Radiation Oncology
Emory University School of Medicine
1365 Clifton Road, N.E.
Atlanta, GA 30322
Tel: (404)-778-3473
Fax: (404) 778-4139
Email: wcurran@emory.edu
Adam Dicker, MD, PhD
Professor & Chair, Dept of Radiation Oncology
Jefferson Medical College of Thomas Jefferson University & Hospitals
Kimmel Cancer Center, an NCI designated Cancer Center
111 South 11th Street
Room G-301, Bodine Center
Philadelphia, PA 19107
Tel: (215) 955-6700
Fax: (215) 503-0013
Email: adamdicker@mac.com
Lawrence True, MD
Professor Pathology
Room BB220
Dept of Pathology, Box 356100
1959 NE Pacific St.
University of Washington Medical Center
Seattle, WA, 98195-6100
Tel: (206) 598-4027
Fax: (206) 598-3803
Pager (when in town): (206) 344-0584
Email: ltrue@uw.edu
27
Jeff Simko
Richard C. Friedberg, MD, PhD, FCAP
Chair, Department of Pathology
Medical Director, Baystate Reference Laboratories
Professor and Deputy Chairman
Department of Pathology
Tufts University School of Medicine
759 Chestnut Street
Springfield, MA 01199
Tel: (413) 794-4500
Fax: (413) 794-5893
email: richard.friedberg@baystatehealth.org
Colin Collins, PhD
Professor, Department of Urologic Sciences, University of British Columbia
Vancouver Prostate Centre
Jack Bell Research Centre
2660 Oak Street
Vancouver, BC V6H 3Z6
Phone: (604) 875-4818
Fax: (604) 875-5654
Email: Colin Collins (ccollins@prostatecentre.com)
Waldman, Frederic, MD, PhD
Medical Director, Cancer Diagnostics
Quest Diagnostics Nichols Institute
Hematology/Oncology Department
33608 Ortega Highway
San Juan Capistrano, CA 92675
949-728-4008
Email: Frederic.M.Waldman@questdiagnostics.com
Internal Referees:
Peter Carroll, MD, MPH: Professor and Chair, UCSF Department of Urology
Mack Roach III, MD: Professor and Chair, UCSF Department of Radiation Oncology
Linda Ferrell, MD: Professor and Vice Chair, UCSF Department of Anatomic Pathology
Richard Jordan, DDS,PhD: Professor and Associate Dean of Research, UCSF Department of Orofacial
Sciences
28
Was this manual useful for you? yes no
Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Download PDF

advertising